Clinical trials: Acromegaly
Acromegaly
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
The morbidity and the mortality in acromegalic patients closely correspond to growth hormone (GH) levels and therefore efficient long-term treatment is important.
- Trial name
- NCT00145405
- Testing
- Lanreotide Autogel and Octreotide LAR
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Odense University Hospital
Acromegaly
Estrogen Treatment in Acromegalic Women
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.
- Trial name
- NCT00315107
- Testing
- Alesse
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Université de Montréal
Acromegaly
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly
OBJECTIVES: I. Determine whether release of endogenous growth hormone (GH)-releasing hormone is involved in GH responses to clonidine, pyridostigmine, levodopa, arginine, GH-releasing peptide, insulin-induced hypoglycemia, and…
- Trial name
- NCT00004332
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Acromegaly
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
OBJECTIVES: I. Compare growth hormone (GH) levels at baseline and after glucose suppression measured with both a polyclonal radioimmunoassay and a highly sensitive immunoradiometric assay (IRMA) in patients with acromegaly and…
- Trial name
- NCT00005100
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)